|

Harald Ekman
David V. Goeddel, Ph.D.
Richard Klausner, M.D.
Magnus Persson, M.D., Ph.D.
Peter Svennilson

David Baltimore, Ph.D.
Michael S. Brown, M.D.
Joseph L. Goldstein, M.D.
Tom Maniatis, Ph.D.

Tim Kutzkey, Ph.D.
Gregory S. Naeve, Ph.D.
Dee Datta, Ph.D.

Grant Heidrich

|
|
 |
 |
PTC is a biopharmaceutical company focused
on the discovery, development and commercialization of orally
administered small-molecule drugs that target post-transcriptional
control processes, permitting the inhibition or enhancement of protein
production. The Company’s lead program, Ataluren (PTC124), is the first
investigational new drug designed to enable the formation of a
functioning protein in patients with genetic disorders due a nonsense
mutation. Ataluren is currently in advanced clinical development for
multiple indications, including cystic fibrosis and Duchenne muscular
dystrophy. |
PTC Therapeutics, Inc.
South Plainfield, NJ |
 |
 |
Aragon’s recent discoveries show that the
biology of hormone resistant cancers can be overcome through the
creation of a new class of nuclear receptor targeting drugs, opening the
door to a pipeline of new anti-endocrine therapies. The Company’s
approach will produce drugs that are mechanistically distinct from
therapies that are either in the clinic or currently being developed. |
Aragon Pharmaceuticals, Inc.
San Diego, CA |
 |
 |
Igenica is dedicated to the discovery and
development of breakthrough antibody-based therapeutics for the
treatment of cancer. The Company has developed two unique technology
platforms, which collectively offer a function-orientated screening
strategy to systematically identify new tumor antigens and effective
monoclonal antibody drug candidates. |
Igenica, Inc.
Burlingame, CA |
 |
 |
3-V’s mission is to discover and develop drugs with broad-spectrum
antiviral activity and low likelihood of resistance, using a new
platform that allows the identification of host proteins as drug
targets. Initially, the Company will focus on the discovery and
development of drugs against influenza virus, respiratory syncytial
virus and rhinovirus. |
3-V Biosciences, Inc.
Palo Alto, CA |
 |
 |
NGM uses a combination novel experimental approaches to exploit
emerging human biology for the development of novel therapies for
metabolic and cardiovascular disease. Initially, the Company will focus
on the gastrointestinal endocrine system and stem cell biology with a
view toward identifying novel factors implicated in type 2 diabetes. |
NGM Biopharmaceuticals, Inc.
South San Francisco, CA |
 |
 |
Constellation is the first biopharmaceutical company
dedicated to the development of novel therapeutics in the emerging field
of Epigenetics, a new field of science involving selective regulators
that are critical to controlling gene expression. While the Company is
initially focused on oncology, its technology platform will likely be
applicable to other therapeutic areas, including autoimmune,
inflammatory and neurological diseases. |
Constellation Pharmaceuticals, Inc.
Cambridge, MA |
 |
 |
Immune Design is a new generation vaccine company built on emerging
understanding of the role of dendritic cells in determining an effective
immune response. The Company is employing improved adjuvants and novel
technologies that target and control dendritic cells in an unprecedented
manner. This approach could create an entirely new generation of
prophylactic and therapeutic vaccines for infectious diseases and extend
the coverage of current vaccines. |
Immune Design Corp.
Seattle, WA |
|